LeCointe-Cephas Lisa 4
4 · Merck & Co., Inc. · Filed May 4, 2022
Insider Transaction Report
Form 4
LeCointe-Cephas Lisa
SVP Chief Ethics & Com Officer
Transactions
- Exercise/Conversion
Common Stock
2022-05-03$87.65/sh+452$39,618→ 3,284.781 total - Exercise/Conversion
Restricted Stock Unit
2022-05-03−452→ 0 totalFrom: 2020-05-03Exp: 2022-05-03→ Common Stock (452 underlying) - Tax Payment
Common Stock
2022-05-03$87.65/sh−155$13,586→ 3,129.781 total
Footnotes (4)
- [F1]Holdings include shares acquired in dividend reinvestment transactions.
- [F2]Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
- [F3]Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- [F4]These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.